Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)

US9688742B2 · kind B2 · utility

Assignees

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• INSTITUT NATIONAL DE LA RECHERCHE AGRONOMQIUE · FR
• UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR

Inventors

• Nathalie Vergnolle · Toulouse, FR
• Jean-Michel Sallenave · Paris, FR
• Philippe Langella · Vélizy-Villacoublay, FR
• Luis Bermudez-Humaran · Vélizy-Villacoublay, FR

Key dates

• Filing date: Sep 18, 2014
• Grant date: Jun 27, 2017
• Expiry date: Sep 18, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/746
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.